Citius Pharmaceuticals Inc (CTXR) 0.7825 $CTXR
Looking for "Firsts" in Health Care? Check Out Upcoming Catalysts for Citius Pharmaceuticals
PR Newswire - Thu Aug 04, 9:13AM CDT
By Sara Bowman, Senior Staff Writer, Online Media Group, Inc.
Citius Pharmaceuticals Provides Shareholder Update on Recent Achievements
PR Newswire - Mon Aug 01, 6:00AM CDT
Citius Pharmaceuticals, Inc. ("Citius"
(OTC BB: CTXR), a specialty pharmaceutical company dedicated to developing and commercializing adjunctive cancer care and critical care drug products, today provided shareholders with an update regarding the company's recent more notable achievements.
OTCQX and OTCQB Companies to Present at 2016 Marcum MicroCap Conference
PR Newswire - Tue May 31, 5:49PM CDT
OTC Markets Group Inc. (OTCQX: OTCM), operator of financial markets for 10,000 U.S. and global securities, today announced the lineup of OTCQX® Best and OTCQB® Venture Market companies presenting at the Marcum MicroCap Conference, taking place June 1-2nd at the Grand Hyatt New York. The Marcum MicroCap Conference, is dedicated to providing a forum where publicly traded companies with less than $500 million in market capitalization can network with the investment community. The Conference will feature presentations by CEOs and CFOs from various industry sectors, expert panels, and the opportunity to meet with management of presenting companies on a one-on-one basis.
LTEA: 5.24 (+0.23)
Citius Pharmaceuticals Completes Acquisition of Leonard-Meron Biosciences
PR Newswire - Mon Apr 04, 6:00AM CDT
Citius Pharmaceuticals, Inc. (OTCQB: CTXR) ("Citius" today announced completion of the acquisition of Leonard-Meron Biosciences, Inc. ("LMB". Pursuant to the acquisition, Citius acquired all of the outstanding shares of LMB common stock in exchange for shares of Citius common stock.
Citius Pharmaceuticals Announces Significant Equity Investment from Chairman and CEO
PR Newswire - Wed Mar 23, 6:00AM CDT
Citius Pharmaceuticals, Inc.,"Citius" (OTCQB: CTXR) or the "Company", today announced that Chairman and CEO Leonard Mazur has purchased 5 million of its restricted shares from the Company for $3 million dollars. This substantial investment will enable the Company to continue its development efforts across its product portfolio, and to build the infrastructure necessary to support multiple product development efforts.
Citius Pharmaceuticals Signs Letter of Intent to Acquire Leonard Meron Biosciences
PR Newswire - Mon Mar 07, 6:00AM CST
Citius Pharmaceuticals, Inc.,"Citius" (OTCQB: CTXR) today announced that the Company has entered into a non-binding letter of intent to acquire all of the outstanding shares of Leonard Meron Biosciences, Inc. (LMB). LMB's lead drug candidate, Mino-Lok(TM), is an antibiotic lock solution used to treat patients with catheter-related bloodstream infections, or CRBSIs. Mino-Lok(TM) is a patent-protected, novel solution containing minocycline, edetate (disodium EDTA), and ethyl alcohol, which act to break down bacterial biofilms, eradicate the bacteria, provide anti-clotting properties to maintain patency in CVCs, and salvage the indwelling catheter. Mino-Lok(TM) is entering phase 3 trials after demonstrating safety in its phase 2b trial conducted at the MD Anderson Cancer Center in Houston. Recently, the U.S. Food and Drug Administration (FDA) granted a Qualified Infectious Disease Product (QIDP) designation for Mino-Lok. Receiving QIDP designation means that Mino-Lok(TM) is now eligible for Fast Track designation, Priority Review for development, and a five-year extension of market exclusivity. The Company believes that the commercial target for Mino-Lok(TM) represents a significant opportunity in the multi-billion, critical care market.
Citius Pharmaceuticals Announces Results from Phase 2a Trial of Hydrocortisone and Lidocaine Combination Cream in Patients with Grade I and II Hemorrhoids
PR Newswire - Mon Feb 01, 6:00AM CST
Citius Pharmaceuticals, Inc. (OTCQB: CTXR) today announced top line data from the first Phase 2a clinical trial of hydrocortisone acetate (HC) and lidocaine hydrochloride (L) as single agents and in combination (HC+L) in patients with grade I and II hemorrhoids. Citius' hydrocortisone and lidocaine cream is targeting to become the first FDA -approved prescription product to treat hemorrhoids in the U.S.
Citius Pharmaceuticals, Inc. Announces Appointment of Mr. Suren Dutia to Its Board of Directors
PR Newswire - Thu Oct 08, 6:00AM CDT
Citius Pharmaceuticals, Inc. (OTCQB: CTXR), (the "Company" announced today that it has appointed Mr. Suren Dutia to the board of directors effective October 8, 2015.
Citius Pharmaceuticals Announces Myron Holubiak, Former President of Roche Laboratories, Inc., USA, has Joined Its Board of Directors
PR Newswire - Tue Oct 06, 6:00AM CDT
Citius Pharmaceuticals, Inc. (OTCQB: CTXR), (the "Company" announced today that it has appointed Mr. Myron Holubiak to the board of directors effective October 1, 2015.
BIOS: 2.60 (-0.01), ASMB: 6.06 (+0.17)
Looking for "Firsts" in Health Care? Check Out Upcoming Catalysts for Citius Pharmaceuticals
PR Newswire - Thu Aug 04, 9:13AM CDT
By Sara Bowman, Senior Staff Writer, Online Media Group, Inc.
Citius Pharmaceuticals Provides Shareholder Update on Recent Achievements
PR Newswire - Mon Aug 01, 6:00AM CDT
Citius Pharmaceuticals, Inc. ("Citius"
(OTC BB: CTXR), a specialty pharmaceutical company dedicated to developing and commercializing adjunctive cancer care and critical care drug products, today provided shareholders with an update regarding the company's recent more notable achievements. OTCQX and OTCQB Companies to Present at 2016 Marcum MicroCap Conference
PR Newswire - Tue May 31, 5:49PM CDT
OTC Markets Group Inc. (OTCQX: OTCM), operator of financial markets for 10,000 U.S. and global securities, today announced the lineup of OTCQX® Best and OTCQB® Venture Market companies presenting at the Marcum MicroCap Conference, taking place June 1-2nd at the Grand Hyatt New York. The Marcum MicroCap Conference, is dedicated to providing a forum where publicly traded companies with less than $500 million in market capitalization can network with the investment community. The Conference will feature presentations by CEOs and CFOs from various industry sectors, expert panels, and the opportunity to meet with management of presenting companies on a one-on-one basis.
LTEA: 5.24 (+0.23)
Citius Pharmaceuticals Completes Acquisition of Leonard-Meron Biosciences
PR Newswire - Mon Apr 04, 6:00AM CDT
Citius Pharmaceuticals, Inc. (OTCQB: CTXR) ("Citius"
today announced completion of the acquisition of Leonard-Meron Biosciences, Inc. ("LMB". Pursuant to the acquisition, Citius acquired all of the outstanding shares of LMB common stock in exchange for shares of Citius common stock. Citius Pharmaceuticals Announces Significant Equity Investment from Chairman and CEO
PR Newswire - Wed Mar 23, 6:00AM CDT
Citius Pharmaceuticals, Inc.,"Citius" (OTCQB: CTXR) or the "Company", today announced that Chairman and CEO Leonard Mazur has purchased 5 million of its restricted shares from the Company for $3 million dollars. This substantial investment will enable the Company to continue its development efforts across its product portfolio, and to build the infrastructure necessary to support multiple product development efforts.
Citius Pharmaceuticals Signs Letter of Intent to Acquire Leonard Meron Biosciences
PR Newswire - Mon Mar 07, 6:00AM CST
Citius Pharmaceuticals, Inc.,"Citius" (OTCQB: CTXR) today announced that the Company has entered into a non-binding letter of intent to acquire all of the outstanding shares of Leonard Meron Biosciences, Inc. (LMB). LMB's lead drug candidate, Mino-Lok(TM), is an antibiotic lock solution used to treat patients with catheter-related bloodstream infections, or CRBSIs. Mino-Lok(TM) is a patent-protected, novel solution containing minocycline, edetate (disodium EDTA), and ethyl alcohol, which act to break down bacterial biofilms, eradicate the bacteria, provide anti-clotting properties to maintain patency in CVCs, and salvage the indwelling catheter. Mino-Lok(TM) is entering phase 3 trials after demonstrating safety in its phase 2b trial conducted at the MD Anderson Cancer Center in Houston. Recently, the U.S. Food and Drug Administration (FDA) granted a Qualified Infectious Disease Product (QIDP) designation for Mino-Lok. Receiving QIDP designation means that Mino-Lok(TM) is now eligible for Fast Track designation, Priority Review for development, and a five-year extension of market exclusivity. The Company believes that the commercial target for Mino-Lok(TM) represents a significant opportunity in the multi-billion, critical care market.
Citius Pharmaceuticals Announces Results from Phase 2a Trial of Hydrocortisone and Lidocaine Combination Cream in Patients with Grade I and II Hemorrhoids
PR Newswire - Mon Feb 01, 6:00AM CST
Citius Pharmaceuticals, Inc. (OTCQB: CTXR) today announced top line data from the first Phase 2a clinical trial of hydrocortisone acetate (HC) and lidocaine hydrochloride (L) as single agents and in combination (HC+L) in patients with grade I and II hemorrhoids. Citius' hydrocortisone and lidocaine cream is targeting to become the first FDA -approved prescription product to treat hemorrhoids in the U.S.
Citius Pharmaceuticals, Inc. Announces Appointment of Mr. Suren Dutia to Its Board of Directors
PR Newswire - Thu Oct 08, 6:00AM CDT
Citius Pharmaceuticals, Inc. (OTCQB: CTXR), (the "Company"
announced today that it has appointed Mr. Suren Dutia to the board of directors effective October 8, 2015. Citius Pharmaceuticals Announces Myron Holubiak, Former President of Roche Laboratories, Inc., USA, has Joined Its Board of Directors
PR Newswire - Tue Oct 06, 6:00AM CDT
Citius Pharmaceuticals, Inc. (OTCQB: CTXR), (the "Company"
announced today that it has appointed Mr. Myron Holubiak to the board of directors effective October 1, 2015. BIOS: 2.60 (-0.01), ASMB: 6.06 (+0.17)
